Entasis Therapeutics
As of the edition of 20 October 2026, Entasis Therapeutics runs 4 drugs, 2 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Durlobactam | Ends 2033 (exclusivity) | 0 |
| Zoliflodacin | Ends 2035 (exclusivity) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| DPEP1 Dipeptidase 1 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Entasis Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 4 trials led
- Pregnancy and women's health: 1 trials led
- Urinary and reproductive: 1 trials led